The present disclosure relates to implantable, expandable prosthetic devices and to methods and apparatuses for such prosthetic devices.
The human heart can suffer from various valvular diseases. These valvular diseases can result in significant malfunctioning of the heart and ultimately require replacement of the native valve with an artificial valve. There are a number of known artificial valves and a number of known methods of implanting these artificial valves in humans. Because of the drawbacks associated with conventional open-heart surgery, percutaneous and minimally-invasive surgical approaches are garnering intense attention. In one technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. For example, collapsible transcatheter prosthetic heart valves can be crimped to a compressed state and percutaneously introduced in the compressed state on a catheter and expanded to a functional size at the desired position by balloon inflation or by utilization of a self-expanding frame or stent.
A prosthetic valve for use in such a procedure can include a radially collapsible and expandable frame to which leaflets of the prosthetic valve can be coupled, and which can be percutaneously introduced in a collapsed configuration on a catheter and expanded in the desired position by balloon inflation or by utilization of a self-expanding frame or stent. A challenge in catheter-implanted prosthetic valves is control of perivalvular leakage around the valve, which can occur for a period of time following initial implantation. An additional challenge includes the process of crimping such a prosthetic valve to a profile suitable for percutaneous delivery to a subject.
The foregoing and other objects, features, and advantages of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
In one embodiment, an implantable prosthetic valve can comprise an annular frame, a leaflet structure positioned within the frame, and an outer skirt positioned around an outer surface of the frame. The annular frame can comprise an inflow end and an outflow end and can be radially collapsible and expandable between a radially collapsed configuration and a radially expanded configuration. The outer skirt can comprise pericardial tissue having a fibrous parietal layer defining a first surface of the outer skirt and a serous parietal layer defining a second surface of the outer skirt. The outer skirt can be positioned such that the first surface is facing away from the frame and the second surface is facing towards the frame.
In some embodiments, the outer skirt can comprise bovine pericardial tissue.
In some embodiments, the outer skirt can be laser milled to reduce its thickness.
In some embodiments, the thickness of the outer skirt can be between 50 μm and 150 μm.
In some embodiments, the outer skirt can comprise a plurality of openings or slits.
In some embodiments, at least one of the openings or slits can be elongated in an axial direction.
In some embodiments, the outer skirt can comprise an outflow edge portion and an inflow edge portion. The outflow edge portion can comprise a plurality of alternating projections and notches and the projections can be secured to the frame and the notches can be not directly secured to the frame.
In some embodiments, the prosthetic valve can further comprise a reinforcing strip that wraps around the inflow end of the frame such that a first end portion of the reinforcing strip extends at least partially along an inner surface of the frame and is secured thereto, and a second end portion of the reinforcing strip extends at least partially along an outer surface of the outer skirt and is secured thereto.
In some embodiments, the outer skirt can be secured to the frame with sutures.
In some embodiments, the prosthetic valve can further comprise an inner skirt positioned around an inner surface of the frame and secured thereto.
In some embodiments, the inner skirt can comprise an outflow edge portion secured to the frame and an inflow edge portion that wraps around the inflow end of the frame and the inflow end of the outer skirt. In such embodiments, the inflow end portion can extend at least partially along an outer surface of the outer skirt and can be secured thereto.
In some embodiments, the prosthetic valve can further comprise one or more strips positioned around an outer surface of the outer skirt and secured thereto.
In some embodiments, the strips can comprise a fabric material.
In another embodiment, a method of manufacturing a prosthetic heart valve can comprise providing a piece of pericardial tissue comprising a fibrous parietal layer and a serous parietal layer, reducing the thickness of the piece of pericardial tissue by removing a portion of the serous parietal layer, and positioning the pericardial tissue around an outer surface of a frame of the prosthetic heart valve and securing it thereto. The fibrous parietal layer can define a first surface of the tissue and the serous parietal layer can define a second surface of the tissue. The pericardial tissue can be positioned around the frame such that the first surface is facing away from the frame and the second surface is facing towards the frame.
In some embodiments, the pericardial tissue can have a thickness between 50 μm and 100 μm.
In some embodiments, the act of reducing the thickness of the piece of pericardial tissue can comprise laser milling the serous parietal layer.
In some embodiments, the method can further comprise forming slits or openings in the piece of pericardial tissue before positioning it on the frame.
In some embodiments, the method can further comprise connecting a plurality of prosthetic leaflets to the inside of the frame.
In another embodiment a method of implanting a prosthetic heart valve can comprise inserting a distal end portion of a delivery apparatus and a prosthetic heart valve coupled to the distal end portion of the delivery apparatus into a patient's body, positioning the prosthetic heart valve adjacent a native valve of the patient's heart, and radially expanding the prosthetic heart valve. The prosthetic heart valve can comprise an annular frame, a leaflet structure positioned within the frame and secured thereto, and an outer skirt positioned around an outer surface of the frame. The annular frame can comprise an inflow end and an outflow end and can be radially collapsible and expandable between a radially collapsed configuration and a radially expanded configuration. The outer skirt can comprise pericardial tissue having a fibrous parietal layer defining an outer surface of the skirt and a serous parietal layer defining an inner surface of the skirt. The prosthetic heart valve can be expanded such that the fibrous parietal layer can contact the surrounding native tissue.
In some embodiments, the outer skirt can comprise a plurality of slits or openings such that antegrade blood can flow through the slits or openings.
The valvular structure 14 can comprise three leaflets 41, collectively forming a leaflet structure, which can be arranged to collapse in a tricuspid arrangement, as best shown in
The bare frame 12 is shown in
Suitable plastically-expandable materials that can be used to form the frame 12 include, without limitation, stainless steel, a biocompatible, high-strength alloys (e.g., a cobalt-chromium or a nickel-cobalt-chromium alloys), polymers, or combinations thereof. In particular embodiments, frame 12 is made of a nickel-cobalt-chromium-molybdenum alloy, such as MP35N® alloy (SPS Technologies, Jenkintown, Pennsylvania), which is equivalent to UNS R30035 alloy (covered by ASTM F562-02). MP35N® alloy/UNS R30035 alloy comprises 35% nickel, 35% cobalt, 20% chromium, and 10% molybdenum, by weight. When MP35N® alloy is used as the frame material, as compared to stainless steel, less material is needed to achieve the same or better performance in radial and crush force resistance, fatigue resistances, and corrosion resistance. Moreover, since less material is required, the crimped profile of the frame can be reduced, thereby providing a lower profile prosthetic valve assembly for percutaneous delivery to the treatment location in the body.
Referring to
Each commissure window frame portion 30 connects to a respective commissure of the leaflet structure 14. As can be seen each frame portion 30 is secured at its upper and lower ends to the adjacent rows of struts to provide a robust configuration that enhances fatigue resistance under cyclic loading of the prosthetic valve compared to cantilevered struts for supporting the commissures of the leaflet structure. This configuration enables a reduction in the frame wall thickness to achieve a smaller crimped diameter of the prosthetic valve. In particular embodiments, the thickness T of the frame 12 (
The struts and frame portions of the frame collectively define a plurality of open cells of the frame. At the inflow end of the frame 12, struts 22, struts 24, and struts 34 define a lower row of cells defining openings 36. The second, third, and fourth rows of struts 24, 26, and 28 define two intermediate rows of cells defining openings 38. The fourth and fifth rows of struts 28 and 32, along with frame portions 30 and struts 31, define an upper row of cells defining openings 40. The openings 40 are relatively large and are sized to allow portions of the leaflet structure 14 to protrude, or bulge, into and/or through the openings 40 when the frame 12 is crimped in order to minimize the crimping profile.
As best shown in
The frame 12 is configured to reduce, to prevent, or to minimize possible over-expansion of the prosthetic valve at a predetermined balloon pressure, especially at the outflow end portion of the frame, which supports the leaflet structure 14. In one aspect, the frame is configured to have relatively larger angles 42a, 42b, 42c, 42d, 42e between struts, as shown in
In addition, the inflow and outflow ends of a frame generally tend to over-expand more so than the middle portion of the frame due to the “dog-boning” effect of the balloon used to expand the prosthetic valve. To protect against over-expansion of the leaflet structure 14, the leaflet structure desirably is secured to the frame 12 below the upper row of struts 32, as best shown in
In one type of prosthetic valve construction, portions of the leaflets protrude longitudinally beyond the outflow end of the frame when the prosthetic valve is crimped if the leaflets are connected too close to the distal end of the frame. If the delivery catheter on which the crimped prosthetic valve is mounted includes a pushing mechanism or stop member that pushes against or abuts the outflow end of the prosthetic valve (for example, to maintain the position of the crimped prosthetic valve on the delivery catheter), the pushing member or stop member can damage the portions of the exposed leaflets that extend beyond the outflow end of the frame. Another benefit of connecting the leaflets at a location spaced away from the outflow end of the frame is that when the prosthetic valve is crimped on a delivery catheter, the outflow end of the frame 12 rather than the leaflets 41 is the proximal-most component of the prosthetic valve 10. As such, if the delivery catheter includes a pushing mechanism or stop member that pushes against or abuts the outflow end of the prosthetic valve, the pushing mechanism or stop member contacts the outflow end of the frame, and not leaflets 41, so as to avoid damage to the leaflets.
Also, as can be seen in
The main functions of the inner skirt 16 are to assist in securing the valvular structure 14 to the frame 12 and to assist in forming a good seal between the prosthetic valve and the native annulus by blocking the flow of blood through the open cells of the frame 12 below the lower edge of the leaflets. The inner skirt 16 desirably comprises a tough, tear resistant material such as polyethylene terephthalate (PET), although various other synthetic materials or natural materials (e.g., pericardial tissue) can be used. The thickness of the skirt desirably is less than about 0.15 mm (about 6 mil), and desirably less than about 0.1 mm (about 4 mil), and even more desirably about 0.05 mm (about 2 mil). In particular embodiments, the skirt 16 can have a variable thickness, for example, the skirt can be thicker at least one of its edges than at its center. In one implementation, the skirt 16 can comprise a PET skirt having a thickness of about 0.07 mm at its edges and about 0.06 mm at its center. The thinner skirt can provide for better crimping performances while still providing good sealing.
The skirt 16 can be secured to the inside of frame 12 via sutures 70, as shown in
Some fabric skirts comprise a weave of warp and weft fibers that extend perpendicularly to each other and with one set of the fibers extending longitudinally between the upper and lower edges of the skirt. When the metal frame to which such a fabric skirt is secured is radially compressed, the overall axial length of the frame increases. However, a fabric skirt with limited elasticity cannot elongate along with the frame and therefore tends to deform the struts of the frame and to prevent uniform crimping.
Referring to
Referring again to
Thus, when the metal frame 12 is crimped (as shown in
In addition, the spacing between the woven fibers or yarns can be increased to facilitate elongation of the skirt in the axial direction. For example, for a PET inner skirt 16 formed from 20-denier yarn, the yarn density can be about 15% to about 30% lower than in a typical PET skirt. In some examples, the yarn spacing of the inner skirt 16 can be from about 60 yarns per cm (about 155 yarns per inch) to about 70 yarns per cm (about 180 yarns per inch), such as about 63 yarns per cm (about 160 yarns per inch), whereas in a typical PET skirt the yarn spacing can be from about 85 yarns per cm (about 217 yarns per inch) to about 97 yarns per cm (about 247 yarns per inch). The oblique edges 86, 88 promote a uniform and even distribution of the fabric material along inner circumference of the frame during crimping so as to facilitate uniform crimping to the smallest possible diameter. Additionally, cutting diagonal sutures in a vertical manner may leave loose fringes along the cut edges. The oblique edges 86, 88 help minimize this from occurring.
In alternative embodiments, the skirt can be formed from woven elastic fibers that can stretch in the axial direction during crimping of the prosthetic valve. The warp and weft fibers can run perpendicularly and parallel to the upper and lower edges of the skirt, or alternatively, they can extend at angles between 0 and 90 degrees relative to the upper and lower edges of the skirt, as described above.
The inner skirt 16 can be sutured to the frame 12 at locations away from the suture line 154 so that the skirt can be more pliable in that area. This configuration can avoid stress concentrations at the suture line 154, which attaches the lower edges of the leaflets to the inner skirt 16.
As noted above, the leaflet structure 14 in the illustrated embodiment includes three flexible leaflets 41 (although a greater or a smaller number of leaflets can be used). Additional information regarding the leaflets, as well as additional information regarding skirt material, can be found, for example, in U.S. patent application Ser. No. 14/704,861, filed May 5, 2015, which is incorporated by reference in its entirety.
The leaflets 41 can be secured to one another at their adjacent sides to form commissures 122 of the leaflet structure. A plurality of flexible connectors 124 (one of which is shown in
As noted above, the inner skirt 16 can be used to assist in suturing the leaflet structure 14 to the frame. The inner skirt 16 can have an undulating temporary marking suture to guide the attachment of the lower edges of each leaflet 41. The inner skirt 16 itself can be sutured to the struts of the frame 12 using sutures 70, as noted above, before securing the leaflet structure 14 to the skirt 16. The struts that intersect the marking suture desirably are not attached to the inner skirt 16. This allows the inner skirt 16 to be more pliable in the areas not secured to the frame and minimizes stress concentrations along the suture line that secures the lower edges of the leaflets to the skirt. As noted above, when the skirt is secured to the frame, the fibers 78, 80 of the skirt (see
After all three commissure tab assemblies are secured to respective window frame portions 30, the lower edges of the leaflets 41 between the commissure tab assemblies can be sutured to the inner skirt 16. For example, as shown in
The tissue 200 can be harvested and prepared for use in an implant using those techniques and mechanisms known for processing pericardial tissue for heart valve leaflets. A process for preparing pericardial tissue for heart valve leaflets typically includes first obtaining a fresh pericardial sac from a source animal, and then cutting the sac open along predetermined anatomical landmarks to obtain a parietal pericardial membrane. The parietal pericardial membrane can be flattened and typically cleaned of excess fat and other impurities. After trimming obviously unusable areas, a window or patch of tissue can be fixed, typically by immersing in an aldehyde to cross-link the tissue. Rough edges of the tissue window can be removed and the tissue can be bio-sorted to result in a tissue section. The process of bio-sorting involves visually inspecting the window for unusable areas, and trimming the section therefrom. Further details regarding the process for processing pericardial tissue are disclosed in U.S. Pat. Nos. 8,846,390 and 9,358,107, which are incorporated herein by reference in their entirety.
In the illustrated example of
In addition to laser tissue removal described above, various mechanical devices for skiving or shaving tissue such as razor or planing devices may be used to remove some of the tissue. For instance, a device having a flat platen over which a planing razor or blade translates may be substituted for the linear laser configuration of
In alternative embodiments, the thickness of the pericardial tissue 200 can be reduced by removing a portion of the fibrous parietal layer using any of the techniques described above in lieu of or in addition to removing a portion of the serous parietal layer.
Referring to
Referring to
In the illustrated example of
Referring to
The intermediate portion 406 can comprise a plurality of slits or openings 414. The slits 414 can be cut or otherwise formed in a longitudinal direction (i.e., an axial direction when the outer skirt 400 is attached to the frame of a prosthetic heart valve). The slits 414 can be laser cut or formed by any other means. In the illustrated embodiment of
In some embodiments, each slit 414 includes first and second opposing longitudinal sides 432a, 432b, respectively, that are spaced apart from each other to define a permanent open gap therebetween. In other embodiments, the longitudinal sides 432a, 432b of a slit 414 are in contact with each other (and do not define a permanent open gap therebetween) in the absence of hemodynamic forces, but can move away from each other under hemodynamic forces to allow blood to flow through the skirt via the slits 414.
In the illustrated embodiment of
Referring to
Referring to
The lower edge portion 50 of the inner skirt 16 can be wrapped around the inflow end portion 15 of the frame 12 and around the lower edge portion 404 of the outer skirt 400. The lower edge portion 404 of the outer skirt 400 and the wrapped lower edge portion 50 of the inner skirt 16 can be secured together and/or secured to the frame 12, such as with sutures 470 and/or an adhesive. Wrapping the lower edge portion 50 of the inner skirt 16 around the lower edge portion 404 of the outer skirt 400 can reinforce the lower edge portion 404 and the sutures 470 along the lower edge portion 404. The lower edge portions 50 and 404 are shown loosely attached to the frame in
Although not shown in
The first edge portion 450 of the reinforcing strip 448 can be positioned inside of the frame 12 while the second edge portion 452 can be positioned outside the frame 12. The first and second edge portions 450, 452 can be attached to each other and/or to the frame 12, using sutures 470 and/or an adhesive. The edge portions 450, 452 are shown loosely attached to the frame in
The second edge portion 452 of the reinforcing strip 448 can be wrapped around the lower edge portion 404 of the outer skirt 400 such that the lower edge portion 404 is between the frame 12 and the reinforcing strip 448. The lower edge portion 404 of the outer skirt 400 can be secured to the frame 12 and the second edge portion 452 of the reinforcing strip 448 with the sutures 470 and/or an adhesive. As depicted in
Referring to
The prosthetic valve 10 can be configured for and mounted on a suitable delivery apparatus for implantation in a subject. Several catheter-based delivery apparatuses can be used; a non-limiting example of a suitable catheter-based delivery apparatus includes that disclosed in U.S. Patent Application Publication No. 2013/0030519, which is incorporated by reference herein in its entirety, and U.S. Patent Application Publication No. 2012/0123529.
To implant a plastically-expandable prosthetic valve 10 within a patient, the prosthetic valve 10 including the outer skirt 400 (or alternatively, the outer skirt 300 or 500) can be crimped on an elongated shaft 180 of a delivery apparatus, as best shown in
Alternatively, a self-expanding prosthetic valve 10 can be crimped to a radially collapsed configuration and restrained in the collapsed configuration by inserting the prosthetic valve 10, including the outer skirt 400, into a sheath or equivalent mechanism of a delivery catheter. The prosthetic valve 10 can then be percutaneously delivered to a desired implantation location. Once inside the body, the prosthetic valve 10 can be advanced from the delivery sheath, which allows the prosthetic valve to expand to its functional state.
General Considerations
It should be understood that the disclosed valves can be implanted in any of the native annuluses of the heart (e.g., the pulmonary, mitral, and tricuspid annuluses), and can be used with any of various approaches (e.g., retrograde, antegrade, transseptal, transventricular, transatrial, etc.). The disclosed prostheses can also be implanted in other lumens of the body. Further, in addition to prosthetic valves, the delivery assembly embodiments described herein can be adapted to deliver and implant various other prosthetic devices such as stents and/or other prosthetic repair devices.
For purposes of this description, certain aspects, advantages, and novel features of the embodiments of this disclosure are described herein. The disclosed methods, apparatus, and systems should not be construed as being limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another. The methods, apparatus, and systems are not limited to any specific aspect or feature or combination thereof, nor do the disclosed embodiments require that any one or more specific advantages be present or problems be solved. For example, an outer skirt for a prosthetic heart valve can include one or more features disclosed with respect to skirt 18, skirt 300, skirt 400, and/or skirt 500.
Although the operations of some of the disclosed embodiments are described in a particular, sequential order for convenient presentation, it should be understood that this manner of description encompasses rearrangement, unless a particular ordering is required by specific language set forth below. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Moreover, for the sake of simplicity, the attached figures may not show the various ways in which the disclosed methods can be used in conjunction with other methods.
As used in this application and in the claims, the singular forms “a,” “an,” and “the” include the plural forms unless the context clearly dictates otherwise. Additionally, the term “includes” means “comprises.” As used herein, the term “and/or” used between the last two of a list of elements means any one or more of the listed elements. For example, the phrase “A, B, and/or C” means “A”, “B”, “C”, “A and B”, “A and C”, “B and C”, or “A, B, and C”.
As used herein, the term “proximal” refers to a position, direction, or portion of a device that is closer to the user and further away from the implantation site. As used herein, the term “distal” refers to a position, direction, or portion of a device that is further away from the user and closer to the implantation site. Thus, for example, proximal motion of a device is motion of the device toward the user, while distal motion of the device is motion of the device away from the user. The terms “longitudinal” and “axial” refer to an axis extending in the proximal and distal directions, unless otherwise expressly defined.
As used herein, the terms “coupled” and “associated” generally mean physically coupled or linked and does not exclude the presence of intermediate elements between the coupled or associated items absent specific contrary language.
As used herein, operations that occur “simultaneously” or “concurrently” occur generally at the same time as one another, although delays in the occurrence of one operation relative to the other due to, for example, spacing, play or backlash between components in a mechanical linkage such as threads, gears, etc., are expressly within the scope of the above terms, absent specific contrary language.
In view of the many possible embodiments to which the principles disclosed herein may be applied, it should be recognized that the illustrated embodiments are only preferred examples and should not be taken as limiting the scope of the disclosure. Rather, the scope of the disclosure is at least as broad as by the following claims.
This application is a continuation of U.S. application Ser. No. 17/229,143, filed Apr. 13, 2021, which is a divisional of U.S. application Ser. No. 16/103,183, filed Aug. 14, 2018, now U.S. Pat. No. 10,973,628, which claims the benefit of U.S. Provisional Application No. 62/547,401, filed Aug. 18, 2017, each of which applications are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
30912 | Hancock | Dec 1860 | A |
3409013 | Berry | Nov 1968 | A |
3548417 | Kisher | Dec 1970 | A |
3587115 | Shiley | Jun 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3714671 | Edwards et al. | Feb 1973 | A |
3755823 | Hancock | Sep 1973 | A |
4035849 | Angell et al. | Jul 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4297749 | Davis et al. | Nov 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4345340 | Rosen | Aug 1982 | A |
4373216 | Klawitter | Feb 1983 | A |
4406022 | Roy | Sep 1983 | A |
4441216 | Ionescu et al. | Apr 1984 | A |
4470157 | Love | Sep 1984 | A |
4477930 | Totten et al. | Oct 1984 | A |
4535483 | Klawitter et al. | Aug 1985 | A |
4574803 | Storz | Mar 1986 | A |
4592340 | Boyles | Jun 1986 | A |
4605407 | Black et al. | Aug 1986 | A |
4612011 | Kautzky | Sep 1986 | A |
4643732 | Pietsch et al. | Feb 1987 | A |
4655771 | Wallsten | Apr 1987 | A |
4692164 | Dzemeshkevich et al. | Sep 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4759758 | Gabbay | Jul 1988 | A |
4762128 | Rosenbluth | Aug 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4787901 | Baykut | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4820299 | Philippe et al. | Apr 1989 | A |
4829990 | Thuroff et al. | May 1989 | A |
4851001 | Taheri | Jul 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4883458 | Shiber | Nov 1989 | A |
4922905 | Strecker | May 1990 | A |
4966604 | Reiss | Oct 1990 | A |
4979939 | Shiber | Dec 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4994077 | Dobben | Feb 1991 | A |
5007896 | Shiber | Apr 1991 | A |
5026366 | Leckrone | Jun 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5047041 | Samuels | Sep 1991 | A |
5059177 | Towne et al. | Oct 1991 | A |
5080668 | Bolz et al. | Jan 1992 | A |
5085635 | Cragg | Feb 1992 | A |
5089015 | Ross | Feb 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5163953 | Vince | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5192297 | Hull | Mar 1993 | A |
5266073 | Wall | Nov 1993 | A |
5282847 | Trescony et al. | Feb 1994 | A |
5295958 | Shturman | Mar 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411055 | Kane | May 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5480424 | Cox | Jan 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5549665 | Vesely et al. | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5558644 | Boyd et al. | Sep 1996 | A |
5571175 | Vanney et al. | Nov 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5591185 | Kilmer et al. | Jan 1997 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5607464 | Trescony et al. | Mar 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5628792 | Lentell | May 1997 | A |
5639274 | Fischell et al. | Jun 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5716417 | Girard et al. | Feb 1998 | A |
5728068 | Leone et al. | Mar 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5855602 | Angell | Jan 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
6027525 | Suh et al. | Feb 2000 | A |
6132473 | Williams et al. | Oct 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6174327 | Mertens et al. | Jan 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6217585 | Houser et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6231602 | Carpentier et al. | May 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6299637 | Shaolian et al. | Oct 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6338740 | Carpentier | Jan 2002 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6352547 | Brown et al. | Mar 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440764 | Focht et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6482228 | Norred | Nov 2002 | B1 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6527979 | Constantz et al. | Mar 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6605112 | Moll et al. | Aug 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6689123 | Pinchasik | Feb 2004 | B2 |
6716244 | Klaco | Apr 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6769161 | Brown et al. | Aug 2004 | B2 |
6783542 | Eidenschink | Aug 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6878162 | Bales et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6936067 | Buchanan | Aug 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7018408 | Bailey et al. | Mar 2006 | B2 |
7096554 | Austin et al. | Aug 2006 | B2 |
7225518 | Eldenschink et al. | Jun 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7276084 | Yang et al. | Oct 2007 | B2 |
7316710 | Cheng et al. | Jan 2008 | B1 |
7318278 | Zhang et al. | Jan 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7422603 | Lane | Sep 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7563280 | Anderson et al. | Jul 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7618447 | Case et al. | Nov 2009 | B2 |
7655034 | Mitchell et al. | Feb 2010 | B2 |
7785366 | Maurer et al. | Aug 2010 | B2 |
7914569 | Nguyen | Mar 2011 | B2 |
7959665 | Pienknagura | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8029556 | Rowe | Oct 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
8128686 | Paul, Jr. et al. | Mar 2012 | B2 |
8167932 | Bourang et al. | May 2012 | B2 |
8291570 | Eldenschink et al. | Oct 2012 | B2 |
8348998 | Pintor et al. | Jan 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8449606 | Eliasen et al. | May 2013 | B2 |
8454685 | Hariton et al. | Jun 2013 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8672999 | Cali et al. | Mar 2014 | B2 |
8747463 | Fogarty et al. | Jun 2014 | B2 |
9078781 | Ryan et al. | Jul 2015 | B2 |
9132007 | Menk et al. | Sep 2015 | B2 |
9295552 | McLean et al. | Mar 2016 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20020026094 | Roth | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020138135 | Duerig et al. | Sep 2002 | A1 |
20020143390 | Ishii | Oct 2002 | A1 |
20020173842 | Buchanan | Nov 2002 | A1 |
20030014105 | Cao | Jan 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030100939 | Yodfat et al. | May 2003 | A1 |
20030158597 | Quiachon et al. | Aug 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20040024452 | Kruse et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040078074 | Anderson et al. | Apr 2004 | A1 |
20040186558 | Pavenik et al. | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050010285 | Lambrecht et al. | Jan 2005 | A1 |
20050075724 | Svanidze et al. | Apr 2005 | A1 |
20050075725 | Rowe | Apr 2005 | A1 |
20050075728 | Nguyen et al. | Apr 2005 | A1 |
20050096736 | Osse et al. | May 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050188525 | Weber et al. | Sep 2005 | A1 |
20050203614 | Forster et al. | Sep 2005 | A1 |
20050203617 | Forster et al. | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20060004469 | Sokel | Jan 2006 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060108090 | Ederer et al. | May 2006 | A1 |
20060149350 | Patel et al. | Jul 2006 | A1 |
20060183383 | Asmus et al. | Aug 2006 | A1 |
20060229719 | Marquez et al. | Oct 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20070005131 | Taylor | Jan 2007 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070010877 | Salahieh et al. | Jan 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070162102 | Ryan et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070203575 | Forster et al. | Aug 2007 | A1 |
20070203576 | Lee et al. | Aug 2007 | A1 |
20070208550 | Cao et al. | Sep 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070260305 | Drews et al. | Nov 2007 | A1 |
20070265700 | Eliasen et al. | Nov 2007 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080114442 | Mitchell et al. | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080183271 | Frawley et al. | Jul 2008 | A1 |
20080208327 | Rowe | Aug 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255660 | Guyenot et al. | Oct 2008 | A1 |
20080275537 | Limon | Nov 2008 | A1 |
20080294248 | Yang et al. | Nov 2008 | A1 |
20090118826 | Khaghani | May 2009 | A1 |
20090125118 | Gong | May 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20090299452 | Eidenschink et al. | Dec 2009 | A1 |
20090319037 | Rowe et al. | Dec 2009 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100198347 | Zakay et al. | Aug 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20110004299 | Essinger et al. | Jan 2011 | A1 |
20110015729 | Jimenez et al. | Jan 2011 | A1 |
20110066224 | White | Mar 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110295363 | Girard | Dec 2011 | A1 |
20110319991 | Hariton et al. | Dec 2011 | A1 |
20120089223 | Nguyen et al. | Apr 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120259409 | Nguyen et al. | Oct 2012 | A1 |
20130023985 | Khairkhahan et al. | Jan 2013 | A1 |
20130046373 | Cartledge et al. | Feb 2013 | A1 |
20130150956 | Yohanan et al. | Jun 2013 | A1 |
20130166017 | Cartledge et al. | Jun 2013 | A1 |
20130190857 | Mitra et al. | Jul 2013 | A1 |
20130274873 | Delaloye et al. | Oct 2013 | A1 |
20130310926 | Hariton | Nov 2013 | A1 |
20130317598 | Rowe et al. | Nov 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140200661 | Pintor et al. | Jul 2014 | A1 |
20140209238 | Bonyuet et al. | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140277417 | Schraut et al. | Sep 2014 | A1 |
20140277419 | Garde et al. | Sep 2014 | A1 |
20140277424 | Oslund | Sep 2014 | A1 |
20140277563 | White | Sep 2014 | A1 |
20140296962 | Cartledge et al. | Oct 2014 | A1 |
20140330372 | Weston et al. | Nov 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350667 | Braido et al. | Nov 2014 | A1 |
20150073545 | Braido | Mar 2015 | A1 |
20150073546 | Braido | Mar 2015 | A1 |
20150135506 | White | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150157455 | Hoang et al. | Jun 2015 | A1 |
20150320556 | Levi et al. | Nov 2015 | A1 |
20170014229 | Nguyen-Thien-Nhon et al. | Jan 2017 | A1 |
20170020663 | White | Jan 2017 | A1 |
20170056164 | Wang | Mar 2017 | A1 |
20170071731 | Dove et al. | Mar 2017 | A1 |
20180028310 | Gurovich et al. | Feb 2018 | A1 |
20180153689 | Maimon et al. | Jun 2018 | A1 |
20180325665 | Gurovich et al. | Nov 2018 | A1 |
20180344456 | Barash et al. | Dec 2018 | A1 |
Number | Date | Country |
---|---|---|
0144167 | Sep 1903 | DE |
2246526 | Mar 1973 | DE |
19532846 | Mar 1997 | DE |
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
19907646 | Aug 2000 | DE |
10049812 | Apr 2002 | DE |
10049813 | Apr 2002 | DE |
10049814 | Apr 2002 | DE |
10049815 | Apr 2002 | DE |
0103546 | Mar 1984 | EP |
0850607 | Jul 1998 | EP |
1057460 | Dec 2000 | EP |
1088529 | Apr 2001 | EP |
1570809 | Sep 2005 | EP |
2788217 | Jul 2000 | FR |
2815844 | May 2002 | FR |
2056023 | Mar 1981 | GB |
1271508 | Nov 1986 | SU |
9117720 | Nov 1991 | WO |
9217118 | Oct 1992 | WO |
9301768 | Feb 1993 | WO |
9724080 | Jul 1997 | WO |
9829057 | Jul 1998 | WO |
9930646 | Jun 1999 | WO |
9933414 | Jul 1999 | WO |
9940964 | Aug 1999 | WO |
9947075 | Sep 1999 | WO |
0018333 | Apr 2000 | WO |
0041652 | Jul 2000 | WO |
0135878 | May 2001 | WO |
0149213 | Jul 2001 | WO |
0154624 | Aug 2001 | WO |
0154625 | Aug 2001 | WO |
0162189 | Aug 2001 | WO |
0047139 | Sep 2001 | WO |
0164137 | Sep 2001 | WO |
0176510 | Oct 2001 | WO |
0222054 | Mar 2002 | WO |
0236048 | May 2002 | WO |
0241789 | May 2002 | WO |
0243620 | Jun 2002 | WO |
0247575 | Jun 2002 | WO |
0249540 | Jun 2002 | WO |
03047468 | Jun 2003 | WO |
2005034812 | Apr 2005 | WO |
2005055883 | Jun 2005 | WO |
2005084595 | Sep 2005 | WO |
2006014233 | Feb 2006 | WO |
2006032051 | Mar 2006 | WO |
2006034008 | Mar 2006 | WO |
2006111391 | Oct 2006 | WO |
2006127089 | Nov 2006 | WO |
2006138173 | Dec 2006 | WO |
2005102015 | Apr 2007 | WO |
2007047488 | Apr 2007 | WO |
2007067942 | Jun 2007 | WO |
2007097983 | Aug 2007 | WO |
2008005405 | Jan 2008 | WO |
2008015257 | Feb 2008 | WO |
2008035337 | Mar 2008 | WO |
2008091515 | Jul 2008 | WO |
2008147964 | Dec 2008 | WO |
2008150529 | Dec 2008 | WO |
2009033469 | Mar 2009 | WO |
2009042196 | Apr 2009 | WO |
2009053497 | Apr 2009 | WO |
2009061389 | May 2009 | WO |
2009116041 | Sep 2009 | WO |
2009149462 | Dec 2009 | WO |
2010011699 | Jan 2010 | WO |
2010121076 | Oct 2010 | WO |
2013106585 | Jul 2013 | WO |
2015085218 | Jun 2015 | WO |
2015152980 | Oct 2015 | WO |
Entry |
---|
Saporito, et al. “Bovine pericardium retail preserved in glutaraldehyde and used as a vascular patch.” BMC Surg 11, 37. 2011. https://doi.org/10.1186/1471-2482-11-37. |
Fanning, J.P., et al., “Transcatheter aortic valve implantation (TAVI): valve design and evolution.” International Journal of Cardiology, 2013, vol. 168, No. 3, pp. 1822-1831, <DOI: 10.1016/j.ijcard 2013.07.117>. |
Al-Khaja, et al. “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, vol. 3. pp. 305-311. 1989. |
Bailey, S. “Percutaneous Expandable Prosthetic Valves,” Textbook of Interventional Cardiology vol. 2, 2nd Ed. pp. 1268-1276. 1994. |
Gauvin, R. et al., “A Comparative study of bovine and porcine pericardium to highlight their potential advantages to manufacture percutaneous cardiovascular implants.”, Journal of biomaterials applications, 2013, vol. 28, No. 4, pp. 552-565, <DOI: 10.1177/0885328212465482>. |
H.R. Andersen “History of Percutaneous Aortic Valve Prosthesis,” Herz No. 34. pp. 343-346. 2009. |
H.R. Andersen, et al. “Transluminal Implantation of Artificial Heart Valve. Description of a New Expandable Aortic Valve and Initial Results with implantation by Catheter Technique in Closed Chest Pig.” European Heart Journal, No. 13. pp. 704-708. 1992. |
International Search for Report for International Patent Application No. PCT/US2018/046891, completed Dec. 6, 2018. |
Li et al., “The organizational structure of the pericardium” Journal of Biomedical Engineering 1985; 2 (3): 149-156 Journal of Biomedical Engineering, Chengdu University of Science and Technology. |
Pavonik, et al. “Development and initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology, vol. 183, No. 1. pp. 151-154. 1992. |
Ross, “Aortic Valve Surgery,” At a meeting of the Council on Aug. 4, 1966. pp. 192-197. |
Sabbah, et al. “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4. pp. 302-309. 1989. |
Uchida, “Modifications of Gianturco Expandable Wire Stents,” American Journal of Roentgenology, vol. 150. pp. 1185-1187. 1986. |
Wheatley, “Valve Prostheses,” Operative Surgery, 4th ed. pp. 415-424. 1986. |
Number | Date | Country | |
---|---|---|---|
20230063795 A1 | Mar 2023 | US |
Number | Date | Country | |
---|---|---|---|
62547401 | Aug 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16103183 | Aug 2018 | US |
Child | 17229143 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17229143 | Apr 2021 | US |
Child | 18049579 | US |